Publicacións en colaboración con investigadores/as de Hospital de Fuenlabrada (32)

2024

  1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  2. Surgery for inflammatory bowel disease in Spain: How are we doing? Initial results of a nationwide prospective registry

    Cirugia Espanola, Vol. 102, Núm. 7, pp. 355-363

2023

  1. Postoperative Critical Care Admission Was Not Associated with Improved Postoperative Outcomes in Elective Colorectal Surgery: Secondary Analysis Of POWER Trial

    Journal of Gastrointestinal Surgery, Vol. 27, Núm. 10, pp. 2187-2198

  2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study

    Journal of Dermatological Treatment, Vol. 33, Núm. 3, pp. 1329-1338

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  2. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  3. Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study

    Medicina Intensiva, Vol. 45, Núm. 6, pp. 332-346

  4. Impact of the COVID-19 pandemic on tuberculosis management in Spain

    International Journal of Infectious Diseases, Vol. 108, pp. 300-305

  5. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  6. Institutional factors associated with adherence to enhanced recovery protocols for colorectal surgery: Secondary analysis of a multicenter study

    Journal of Clinical Anesthesia, Vol. 74

  7. The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis

    BMC Pregnancy and Childbirth, Vol. 21, Núm. 1

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

  2. Fish oil enriched intravenous lipid emulsions reduce triglyceride levels in non-critically ill patients with TPN and type 2 diabetes. a post-hoc analysis of the INSUPAR study

    Nutrients, Vol. 12, Núm. 6

  3. Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: Secondary analysis of POWER trial

    Minerva Anestesiologica, Vol. 87, Núm. 1, pp. 13-25

  4. Regular insulin added to total parenteral nutrition vs subcutaneous glargine in non-critically ill diabetic inpatients, a multicenter randomized clinical trial: INSUPAR trial

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 388-394

  5. Risk factors for hypoglycemia in inpatients with total parenteral nutrition and type 2 diabetes: A post hoc analysis of the InSUPAR study

    Endocrine Practice, Vol. 26, Núm. 6, pp. 604-611